GemRIS, an implantable drug delivery system from Taris Biomedical that delivers continuous intravesical gemcitabine, shows potential for use in multiple bladder cancer settings. Ongoing and recently completed phase 1 trials in non-muscle-invasive as well as muscle-invasive bladder cancer are yielding promising preliminary results.
European urology focus. 2019 Sep 24 [Epub ahead of print]
Dominic C Grimberg, Ankeet Shah, Brant A Inman
Division of Urology, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA., Division of Urology, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA. Electronic address: .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/31561993